REGENXBIO Inc. (RGNX) is a publicly traded Healthcare sector company. As of August 24, 2026, RGNX trades at $8.08 with a market cap of $707.66M and a P/E ratio of -2.84. RGNX moved -21.64% today. Year to date, RGNX is -25.56%; over the trailing twelve months it is +32.18%. Its 52-week range spans $5.04 to $16.19. Analyst consensus is strong buy with an average price target of $25.75. Rallies surfaces RGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for RGNX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $8.08 |
| Market Cap | $707.66M |
| P/E Ratio | -2.84 |
| EPS | $-3.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.19 |
| 52-Week Low | $5.04 |
| Volume | 917.47K |
| Avg Volume | 0 |
| Revenue (TTM) | $174.48M |
| Net Income | $-196.43M |
| Gross Margin | 0.00% |
8 analysts cover RGNX: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.75.